Understanding arsenic-ulexite interactions in evaporite environments: Evidence from XRPD, micro-XRF, micro-FT-IR, and XPS studies.

World-class borate deposits often form from As-rich waters, this study addresses the understudied association of arsenic (As) species with evaporite borates, focusing on the Puna region's borate deposits (Central Andes of Argentina). The research aims to characterize the association between borate minerals and high As concentrations in brines and thermal waters. To achieve this, five borate samples were collected from the Olaroz salt flat nucleus and thermal springs, alongside associated water samples. Comprehensive analytical techniques, including ICP-MS, ICP-OES, synchrotron-based micro-XRF, XRPD, Rietveld analysis, micro-FT-IR, and XPS, were employed to determine bulk and surface chemical compositions, mineral identification, and solid speciation of As and boron. The study reveals that under oxidizing conditions and in absence of organic matter, aqueous arsenic species interact with ulexite through a stepwise process involving charge neutralization, cationic bridge formation, and surface complex formation with polyborate and As(V) oxyanions. However, in environments associated with microbial mats or organic-rich sediments, the dissolved As(V) is reduced to As(III), which forms complexes with functional groups of organic matter. The coexistence of As(III) and As(V) in specific layers suggests potential remediation strategies targeting organic matter for the removal of the more toxic As(III) in similar geological settings.

Haematological recovery in poor and good haematopoietic stem cell mobilisers.

OBJECTIVES: Evaluate whether poor mobilisers had delayed haematopoietic (neutrophil and platelet) recovery despite receiving similar cell dose as good mobilisers. BACKGROUND: Autologous haematopoietic progenitor cell (HPC) transplantation is indicated to treat some haematological malignancies. This procedure requires HPC mobilisation from bone marrow to peripheral blood. Cell dose is important for a fast haematological recovery. Despite being poor mobilisers, some patients can collect enough cell numbers for transplantation. RESULTS: Fifteen poor mobiliser patients (peak of CD34+ cells ≤10 µL(-1) in peripheral blood) were transplanted at our institution. Haematological recovery (neutrophil ≥ 500 µL(-1) ) in this group was compared to that observed in the group of 16 patients of good mobilisers (peak of CD34+ cells ≥20 µL(-1) in peripheral blood) who received similar cell dose (2·637 ± 0·1744 × 10(6) kg(-1) vs 2·727 ± 0·1746 × 10(6) kg(-1) ; P = 0·7177). The poor mobiliser group had neutrophil and platelet recovery later than the good mobiliser group (on day 12, range 9-14 vs day 10, range 9-22, P = 0·0381 for neutrophil, and on day 22·89 ± 11·16 and 14·08 ± 4·821, P = 0·0193 for platelet). Mortality rates and transfusion requirements were not different between the groups. CONCLUSION: Poor mobilisers have delayed neutrophil and platelet recovery after autologous HPC transplantation despite having received the same cell dose as good mobilisers.